15 / 21
30-05-18
19 December 2016: US FDA-accelerated approval
of
rucaparib monotherapy
for the treatment of
patients with deleterious BRCA mutation (
germline
and/or somatic; as detected by an FDA-approved
companion diagnostic for RUBRACA) associated
advanced ovarian cancer
who have been treated
with ≥2 chemotherapies
2
Study 10 and ARIEL2:
Rucaparib Monotherapy in g
BRCA
/s
BRCA-
Mutated Ovarian Cancer